Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, ...

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

Ensem Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ETX-636, a Potential Best-In-Class Allosteric Pan-Mutant-Selective PI3Kα Inhibitor and Degrader - ETX–636 is ...

WALTHAM, Mass., July 01, 2025--Ensem Therapeutics, Inc. (ENSEM), a clinical stage, oncology-focused biopharmaceutical company, today announced the first patient has been dosed in its phase 1/2 ...

Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II (“Helix”) (Nasdaq: HLXB), a ...

BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies.

In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and ...

In January, it signed a $2.5 billion deal for Scorpion Therapeutics’ experimental oncology drug, STX-478, a novel mutant-selective PI3Kα inhibitor.

In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS.

. In a Phase 2 clinical trial of gedatolisib plus trastuzumab-pkrb as 3L+ therapy in patients with HER2+ metastatic breast cancer (“mBC”), the objective response rate (“ORR”) was 43% . No patients ...